Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study

Abstract Background Polycystic ovarian syndrome (PCOS) is a highly variable syndrome and one of the most common female endocrine disorders. Although the association inositols-glucomannan may represent a good therapeutic strategy in the treatment of PCOS women with insulin resistance, the effect of i...

Full description

Bibliographic Details
Main Authors: Jacopo Troisi, Claudia Cinque, Luigi Giugliano, Steven Symes, Sean Richards, David Adair, Pierpaolo Cavallo, Laura Sarno, Giovanni Scala, Maria Caiazza, Maurizio Guida
Format: Article
Language:English
Published: BMC 2019-03-01
Series:Journal of Ovarian Research
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13048-019-0500-x
id doaj-b1d97f23960b4686b2ea7c7bf4330c71
record_format Article
spelling doaj-b1d97f23960b4686b2ea7c7bf4330c712020-11-25T02:30:47ZengBMCJournal of Ovarian Research1757-22152019-03-0112111110.1186/s13048-019-0500-xMetabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot studyJacopo Troisi0Claudia Cinque1Luigi Giugliano2Steven Symes3Sean Richards4David Adair5Pierpaolo Cavallo6Laura Sarno7Giovanni Scala8Maria Caiazza9Maurizio Guida10Department of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, University of SalernoDepartment of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, University of SalernoDepartment of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, University of SalernoDepartment of Chemistry and Physics, University of Tennessee at ChattanoogaDepartment of Obstetrics and Gynecology, University of Tennessee College of MedicineDepartment of Obstetrics and Gynecology, University of Tennessee College of MedicineDepartment of Physics, University of SalernoDepartment of Neurosciences and Reproductive and Dentistry Sciences, University of Naples Federico IITheoreo srl, Via degli Ulivi 3Azienda Sanitaria Locale, distretto sanitario 66Department of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, University of SalernoAbstract Background Polycystic ovarian syndrome (PCOS) is a highly variable syndrome and one of the most common female endocrine disorders. Although the association inositols-glucomannan may represent a good therapeutic strategy in the treatment of PCOS women with insulin resistance, the effect of inositols on the metabolomic profile of these women has not been described yet. Results Fifteen PCOS-patients and 15 controls were enrolled. Patients were treated with myo-inositol (1.75 g/day), D-chiro-inositol (0.25 g/day) and glucomannan (4 g/day) for 3 months. Blood concentrations of glucose, insulin, triglycerides and cholesterol, and ovary volumes and antral follicles count, as well as metabolomic profiles, were evaluated for control subjects and for cases before and after treatment. PCOS-patients had higher BMI compared with Controls, BMI decreased significantly after 3 months of treatment although it remained significantly higher compared to controls. 3-methyl-1-hydroxybutyl-thiamine-diphosphate, valine, phenylalanine, ketoisocapric, linoleic, lactic, glyceric, citric and palmitic acid, glucose, glutamine, creatinine, arginine, choline and tocopherol emerged as the most relevant metabolites for distinguishing cases from controls. Conclusion Our pilot study has identified a complex network of serum molecules that appear to be correlated with PCOS, and with a combined treatment with inositols and glucomannan. Trial registration ClinicalTial.gov, NCT03608813. Registered 1st August 2018 - Retrospectively registered, .http://link.springer.com/article/10.1186/s13048-019-0500-xPolycystic ovary syndromeInositols-glucomannan associationMetabolomics
collection DOAJ
language English
format Article
sources DOAJ
author Jacopo Troisi
Claudia Cinque
Luigi Giugliano
Steven Symes
Sean Richards
David Adair
Pierpaolo Cavallo
Laura Sarno
Giovanni Scala
Maria Caiazza
Maurizio Guida
spellingShingle Jacopo Troisi
Claudia Cinque
Luigi Giugliano
Steven Symes
Sean Richards
David Adair
Pierpaolo Cavallo
Laura Sarno
Giovanni Scala
Maria Caiazza
Maurizio Guida
Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study
Journal of Ovarian Research
Polycystic ovary syndrome
Inositols-glucomannan association
Metabolomics
author_facet Jacopo Troisi
Claudia Cinque
Luigi Giugliano
Steven Symes
Sean Richards
David Adair
Pierpaolo Cavallo
Laura Sarno
Giovanni Scala
Maria Caiazza
Maurizio Guida
author_sort Jacopo Troisi
title Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study
title_short Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study
title_full Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study
title_fullStr Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study
title_full_unstemmed Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study
title_sort metabolomic change due to combined treatment with myo-inositol, d-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study
publisher BMC
series Journal of Ovarian Research
issn 1757-2215
publishDate 2019-03-01
description Abstract Background Polycystic ovarian syndrome (PCOS) is a highly variable syndrome and one of the most common female endocrine disorders. Although the association inositols-glucomannan may represent a good therapeutic strategy in the treatment of PCOS women with insulin resistance, the effect of inositols on the metabolomic profile of these women has not been described yet. Results Fifteen PCOS-patients and 15 controls were enrolled. Patients were treated with myo-inositol (1.75 g/day), D-chiro-inositol (0.25 g/day) and glucomannan (4 g/day) for 3 months. Blood concentrations of glucose, insulin, triglycerides and cholesterol, and ovary volumes and antral follicles count, as well as metabolomic profiles, were evaluated for control subjects and for cases before and after treatment. PCOS-patients had higher BMI compared with Controls, BMI decreased significantly after 3 months of treatment although it remained significantly higher compared to controls. 3-methyl-1-hydroxybutyl-thiamine-diphosphate, valine, phenylalanine, ketoisocapric, linoleic, lactic, glyceric, citric and palmitic acid, glucose, glutamine, creatinine, arginine, choline and tocopherol emerged as the most relevant metabolites for distinguishing cases from controls. Conclusion Our pilot study has identified a complex network of serum molecules that appear to be correlated with PCOS, and with a combined treatment with inositols and glucomannan. Trial registration ClinicalTial.gov, NCT03608813. Registered 1st August 2018 - Retrospectively registered, .
topic Polycystic ovary syndrome
Inositols-glucomannan association
Metabolomics
url http://link.springer.com/article/10.1186/s13048-019-0500-x
work_keys_str_mv AT jacopotroisi metabolomicchangeduetocombinedtreatmentwithmyoinositoldchiroinositolandglucomannaninpolycysticovariansyndromepatientsapilotstudy
AT claudiacinque metabolomicchangeduetocombinedtreatmentwithmyoinositoldchiroinositolandglucomannaninpolycysticovariansyndromepatientsapilotstudy
AT luigigiugliano metabolomicchangeduetocombinedtreatmentwithmyoinositoldchiroinositolandglucomannaninpolycysticovariansyndromepatientsapilotstudy
AT stevensymes metabolomicchangeduetocombinedtreatmentwithmyoinositoldchiroinositolandglucomannaninpolycysticovariansyndromepatientsapilotstudy
AT seanrichards metabolomicchangeduetocombinedtreatmentwithmyoinositoldchiroinositolandglucomannaninpolycysticovariansyndromepatientsapilotstudy
AT davidadair metabolomicchangeduetocombinedtreatmentwithmyoinositoldchiroinositolandglucomannaninpolycysticovariansyndromepatientsapilotstudy
AT pierpaolocavallo metabolomicchangeduetocombinedtreatmentwithmyoinositoldchiroinositolandglucomannaninpolycysticovariansyndromepatientsapilotstudy
AT laurasarno metabolomicchangeduetocombinedtreatmentwithmyoinositoldchiroinositolandglucomannaninpolycysticovariansyndromepatientsapilotstudy
AT giovanniscala metabolomicchangeduetocombinedtreatmentwithmyoinositoldchiroinositolandglucomannaninpolycysticovariansyndromepatientsapilotstudy
AT mariacaiazza metabolomicchangeduetocombinedtreatmentwithmyoinositoldchiroinositolandglucomannaninpolycysticovariansyndromepatientsapilotstudy
AT maurizioguida metabolomicchangeduetocombinedtreatmentwithmyoinositoldchiroinositolandglucomannaninpolycysticovariansyndromepatientsapilotstudy
_version_ 1724827950857060352